NASDAQ:INZY Inozyme Pharma (INZY) Stock Price, News & Analysis $4.98 -0.24 (-4.60%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$4.89▼$5.3250-Day Range$4.31▼$5.8352-Week Range$2.69▼$7.80Volume168,094 shsAverage Volume463,556 shsMarket Capitalization$308.04 millionP/E RatioN/ADividend YieldN/APrice Target$16.17 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Inozyme Pharma alerts: Email Address Inozyme Pharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside224.6% Upside$16.17 Price TargetShort InterestBearish9.35% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.80 out of 5 starsMedical Sector749th out of 910 stocksPharmaceutical Preparations Industry351st out of 426 stocks 3.5 Analyst's Opinion Consensus RatingInozyme Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageInozyme Pharma has only been the subject of 4 research reports in the past 90 days.Read more about Inozyme Pharma's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted9.35% of the float of Inozyme Pharma has been sold short.Short Interest Ratio / Days to CoverInozyme Pharma has a short interest ratio ("days to cover") of 12.3, which indicates bearish sentiment.Change versus previous monthShort interest in Inozyme Pharma has recently decreased by 4.81%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldInozyme Pharma does not currently pay a dividend.Dividend GrowthInozyme Pharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for INZY. Previous Next 3.3 News and Social Media Coverage News SentimentInozyme Pharma has a news sentiment score of 1.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Inozyme Pharma this week, compared to 1 article on an average week.Search Interest7 people have searched for INZY on MarketBeat in the last 30 days. This is an increase of 250% compared to the previous 30 days.MarketBeat Follows2 people have added Inozyme Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Inozyme Pharma insiders have not sold or bought any company stock.Percentage Held by Insiders11.19% of the stock of Inozyme Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions88.30% of the stock of Inozyme Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Inozyme Pharma's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Inozyme Pharma are expected to remain at ($1.67) per share in the coming year.Price to Earnings Ratio vs. the MarketThe P/E ratio of Inozyme Pharma is -3.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Inozyme Pharma is -3.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInozyme Pharma has a P/B Ratio of 3.30. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Inozyme Pharma's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Deal MakerThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase, according to the NY Post. With a sky-high 150% turnover rate, the fast food industry is already grappling with labor issues before taking into account these wage hikes. The industry will need a projected 1 million new workers every year through 2032.Learn more about this much-needed advancement and investment opportunity here. About Inozyme Pharma Stock (NASDAQ:INZY)Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.Read More INZY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart INZY Stock News HeadlinesAugust 29, 2024 | globenewswire.comInozyme Pharma to Participate at the 2024 Wells Fargo Healthcare ConferenceAugust 14, 2024 | msn.com3 Best Stocks to Buy Now, 8/13/2024, According to Top AnalystsSeptember 7, 2024 | Deal Maker (Ad)The solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase, according to the NY Post. With a sky-high 150% turnover rate, the fast food industry is already grappling with labor issues before taking into account these wage hikes. The industry will need a projected 1 million new workers every year through 2032.August 12, 2024 | finance.yahoo.comInstitutional owners may consider drastic measures as Inozyme Pharma, Inc.'s (NASDAQ:INZY) recent US$49m drop adds to long-term lossesAugust 8, 2024 | uk.investing.comInozyme Pharma announces $23.8 million remaining in ATM programAugust 6, 2024 | markets.businessinsider.comInozyme Pharma Reports Second Quarter 2024 Financial Results and Provides Business HighlightsAugust 6, 2024 | msn.comInozyme Pharma GAAP EPS of -$0.44July 27, 2024 | markets.businessinsider.comAnalysts’ Top Healthcare Picks: Inozyme Pharma (INZY), Glaukos (GKOS)September 7, 2024 | Deal Maker (Ad)The solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase, according to the NY Post. With a sky-high 150% turnover rate, the fast food industry is already grappling with labor issues before taking into account these wage hikes. The industry will need a projected 1 million new workers every year through 2032.July 25, 2024 | globenewswire.comInozyme Pharma Publishes Preclinical Data Supporting INZ-701 as a Potential Therapy for a Broad Range of Serious Rare Diseases Impacting Bone Health and Blood Vessel FunctionJuly 2, 2024 | globenewswire.comInozyme Pharma Announces FDA Fast Track Designation for INZ-701 in ABCC6 DeficiencyJune 21, 2024 | globenewswire.comInozyme Pharma Announces Presentation and Sponsored Symposium at the 11th International Conference on Children's Bone Health (ICCBH)May 23, 2024 | globenewswire.comInozyme Pharma to Present Recently Announced Data from Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE) at Upcoming Medical ConferencesMay 8, 2024 | finanznachrichten.deInozyme Pharma Inc.: Inozyme Pharma Reports First Quarter 2024 Financial Results and Provides Business HighlightsMay 8, 2024 | msn.comInozyme Pharma GAAP EPS of -$0.38 beats by $0.02May 8, 2024 | markets.businessinsider.comInozyme Pharma Buy Rating Affirmed on Strong Trial Results and Robust Pipeline ProspectsMay 8, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Inozyme Pharma (INZY), Esperion (ESPR) and Madrigal Pharmaceuticals (MDGL)May 8, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Cogent Biosciences (COGT) and Inozyme Pharma (INZY)See More Headlines Receive INZY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Inozyme Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/06/2024Today9/07/2024Next Earnings (Estimated)11/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:INZY CUSIPN/A CIK1693011 Webwww.inozyme.com Phone857-330-4340FaxN/AEmployees50Year FoundedN/APrice Target and Rating Average Stock Price Target$16.17 High Stock Price Target$23.00 Low Stock Price Target$14.00 Potential Upside/Downside+224.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.37) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-71,170,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-68.93% Return on Assets-47.92% Debt Debt-to-Equity Ratio0.48 Current Ratio9.84 Quick Ratio9.84 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.51 per share Price / Book3.30Miscellaneous Outstanding Shares61,856,000Free Float54,934,000Market Cap$308.04 million OptionableOptionable Beta1.52 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesDr. Douglas A. Treco Ph.D. (Age 66)CEO & Chairman Comp: $591.88kMr. Axel Bolte M.B.A. (Age 52)M.Sc., Co-Founder, Senior Advisor & Director Comp: $1.16MMr. Sanjay S. Subramanian M.B.A. (Age 47)M.S., Senior VP, CFO, Principal Accounting Officer & Corporate Secretary Comp: $626.23kDr. Matthew Winton Ph.D. (Age 46)Senior VP & COO Comp: $526.43kDr. Demetrios Braddock M.D.Ph.D., Co-Founder, Scientific Founder, Member of Scientific Advisory Board & Board ObserverDr. Soojin Kim Ph.D.Senior VP & Chief Technical Operations OfficerDr. David Thompson M.A.M.S., Ph.D., Senior VP, Chief Scientific Officer & Chief Development OfficerMr. Stefan RileyDirector of Investor RelationsMs. Gayle GirondaSenior VP & Chief People OfficerDr. Yves Sabbagh Ph.D.Chairman of Scientific Advisory Board & Senior VPMore ExecutivesKey CompetitorsFoghorn TherapeuticsNASDAQ:FHTXZIOPHARM OncologyNASDAQ:ZIOPEagle PharmaceuticalsNASDAQ:EGRXStemline TherapeuticsNASDAQ:STMLArdelyxNASDAQ:ARDXView All CompetitorsInsiders & InstitutionsAffinity Asset Advisors LLCBought 213,733 shares on 8/15/2024Ownership: 4.618%Blue Owl Capital Holdings LPSold 150,000 shares on 8/15/2024Ownership: 1.811%The Manufacturers Life Insurance Company Bought 2,690 shares on 8/15/2024Ownership: 0.035%Deerfield Management Company L.P. Series CBought 11,591 shares on 8/15/2024Ownership: 0.019%AQR Capital Management LLCSold 16,909 shares on 8/15/2024Ownership: 0.017%View All Insider TransactionsView All Institutional Transactions INZY Stock Analysis - Frequently Asked Questions How have INZY shares performed this year? Inozyme Pharma's stock was trading at $4.26 on January 1st, 2024. Since then, INZY stock has increased by 16.9% and is now trading at $4.98. View the best growth stocks for 2024 here. How were Inozyme Pharma's earnings last quarter? Inozyme Pharma, Inc. (NASDAQ:INZY) released its quarterly earnings results on Tuesday, August, 6th. The company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.37) by $0.07. When did Inozyme Pharma IPO? Inozyme Pharma (INZY) raised $75 million in an initial public offering (IPO) on Friday, July 24th 2020. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Securities, Cowen and Piper Sandler served as the underwriters for the IPO and Wedbush PacGrow was co-manager. Who are Inozyme Pharma's major shareholders? Inozyme Pharma's top institutional shareholders include Samlyn Capital LLC (5.42%), Affinity Asset Advisors LLC (4.62%), Millennium Management LLC (2.89%) and Blue Owl Capital Holdings LP (1.81%). Insiders that own company stock include Longitude Capital Partners Iii, Robert Lorne Hopfner, Pivotal Bioventure Partners Fu, Axel Bolte, Henric Bjorn Bjarke and Douglas A Treco. View institutional ownership trends. How do I buy shares of Inozyme Pharma? Shares of INZY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Inozyme Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Inozyme Pharma investors own include Procter & Gamble (PG), RTX (RTX), Cisco Systems (CSCO), CSX (CSX), CVS Health (CVS) and Home Depot (HD). This page (NASDAQ:INZY) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inozyme Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inozyme Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
